Company intelligence / Profile preview

Kadance

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Kadance (formerly healthŌme) offers commercialized genomics-based solutions for hereditary cancer risk screening, pharmacogenomic testing, and precision cancer management. The company partners with insurance carriers to provide these services as living benefits within life and critical illness insurance products[4][6]. It operates a fully integrated in-house genetics lab through its subsidiary Kailos Genetics[7]. Its programs have received industry recognition for innovation in integrating genomics into insurance offerings[6].

Therapeutic areas: OncologyOther
Modalities: Genetic testingPharmacogenomic testing
Industry: Molecular Diagnostics

Partnerships

Hannover Re USChubbGalenusRx

Beyond the preview

Go deeper on Kadance.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kadance.

Explore the full profile